By Nathan Allen

Roche Holding AG (RO.EB) said Friday that long-term data confirm its Gazyva cancer drug extends the lives of people with a chronic form of leukemia compared with its MabThera treatment.

After a follow-up period of five years, data from the final analysis of Roche's CLL11 study show a 51% reduction in the risk of disease progression or death in patients treated with Gazyva, compared with patients treated with its MabThera medication, the company said.

Gazyva is approved for use in combination with chlorambucil in more than 90 countries, Roche said.

Write to Nathan Allen at nathan.allen@dowjones.com

(END) Dow Jones Newswires

June 15, 2018 03:05 ET (07:05 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Roche (QX) Charts.